drugset
drugset / Trial / NCT03718611

To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects

NCT03718611 ↗

Phase 1 Completed 36 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of oral administration of BR9001 compared with BR900A in healthy subjects

Timeline

Start
2018-10-22
Primary completion
2019-03-18
Completion
2019-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BR9001 Unknown — Oral
Subject BR900A Unknown — Oral

Indications

rheumatoid arthritis